EMD 521873

a fusion protein consisting of modified human IL-2 which binds specifically to the high-affinity IL-2 receptor, and an antibody specific for both single- and double-stranded DNA, designed to facilitate the enrichment of IL-2 in tumor tissue

Also Known As:

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Beck, Joachim: 2 articles (01/2013 - 01/2013)
2.	Gallerani, Elisa: 2 articles (01/2013 - 01/2013)
3.	Gillessen, Silke: 2 articles (01/2013 - 01/2013)
4.	Gnad-Vogt, Ulrike S: 2 articles (01/2013 - 01/2013)
5.	Laurent, Julien: 2 articles (01/2013 - 01/2013)
6.	Liedert, Bernd: 2 articles (01/2013 - 01/2013)
7.	Omlin, Aurelius: 2 articles (01/2013 - 01/2013)
8.	Sessa, Cristiana: 2 articles (01/2013 - 01/2013)
9.	Speiser, Daniel E: 2 articles (01/2013 - 01/2013)
10.	Stupp, Roger: 2 articles (01/2013 - 01/2013)

Related Diseases

1.	Necrosis 01/01/2013 - "EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. "
2.	Neoplasms (Cancer) 01/07/2013 - "The results confirm the selectivity of Selectikine with predominant T-cell and low NK cell activation, supporting follow-up studies assessing the clinical efficacy of Selectikine for cancer patients." 01/07/2013 - "Thirty-nine patients with metastatic or locally advanced tumors refractory to standard treatments were treated with increasing doses of Selectikine, and nine further patients received additional cyclophosphamide. " 06/01/2011 - "Relative to the control antibody fusion protein containing wild-type IL-2, NHS-IL2LT retained antitumor activity against established neuroblastoma and non-small cell lung cancer metastases in syngeneic mouse tumor models but was much better tolerated in immune-competent mice and in cynomolgus monkeys. " 01/07/2013 - "T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein." 01/07/2013 - "EMD 521873 (Selectikine or NHS-IL2LT) is a fusion protein consisting of modified human IL-2 which binds specifically to the high-affinity IL-2 receptor, and an antibody specific for both single- and double-stranded DNA, designed to facilitate the enrichment of IL-2 in tumor tissue. "
3.	Neuroblastoma 06/01/2011 - "Relative to the control antibody fusion protein containing wild-type IL-2, NHS-IL2LT retained antitumor activity against established neuroblastoma and non-small cell lung cancer metastases in syngeneic mouse tumor models but was much better tolerated in immune-competent mice and in cynomolgus monkeys. "
4.	Neoplasm Metastasis (Metastasis) 06/01/2011 - "Relative to the control antibody fusion protein containing wild-type IL-2, NHS-IL2LT retained antitumor activity against established neuroblastoma and non-small cell lung cancer metastases in syngeneic mouse tumor models but was much better tolerated in immune-competent mice and in cynomolgus monkeys. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2011 - "Relative to the control antibody fusion protein containing wild-type IL-2, NHS-IL2LT retained antitumor activity against established neuroblastoma and non-small cell lung cancer metastases in syngeneic mouse tumor models but was much better tolerated in immune-competent mice and in cynomolgus monkeys. "

Related Drugs and Biologics

1.	EMD 521873
2.	Interleukin-2 (IL2)
3.	A-Form DNA (A-DNA)
4.	Proteins (Proteins, Gene)
5.	Interleukin-2 Receptors (IL 2 Receptor)
6.	DNA (Deoxyribonucleic Acid)
7.	Cyclophosphamide (Cytoxan)